Lv31
215 积分 2021-04-26 加入
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer
11分钟前
待确认
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS -Mutant Non–Small Cell Lung Cancer
13分钟前
已完结
Bringing atoms to bedside with targeted alpha therapy
9天前
已完结
The landscape for radioligand therapies in oncology
9天前
已完结
Kinase inhibitors trigger target degradation
15天前
已关闭
Human organoids as 3D in vitro platforms for drug discovery: opportunities and challenges
15天前
已完结
Betting on β-catenin inhibitors in oncology
15天前
已完结
Pharmacological targeting of the JAK–STAT pathway: new concepts and emerging indications
15天前
已完结
Site‐Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase
20天前
已完结
KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy
22天前
已完结
皖公网安备34019202002308
